Navigation Links
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
Date:9/5/2012

LOS ANGELES and ROCKVILLE, Md., Sept. 5, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has entered into a collaboration and commercialization agreement with MacroGenics, Inc. Under the terms of the agreement, ImaginAb will develop an anti-CD3 clinical imaging product, for which MacroGenics may receive future milestones and royalties.  In addition, ImaginAb will support the development of companion imaging agents for B7-H3, a novel immune regulator target for which MacroGenics is developing therapeutics.

"Collaborating with MacroGenics provides the opportunity to demonstrate the ways in which ImaginAb's antibody fragment-based imaging technology can be used at the clinical nexus between cancer and immunology," said Dr. Christian Behrenbruch, Chief Executive Officer of ImaginAb. "We are glad to partner on both the B7-H3 and CD3 imaging programs as they are high-potential targets for the treatment of cancer and autoimmune diseases. The  recent clinical successes around key immune-directed targets in cancer, including those involving members of the B7 family of proteins, make these areas of research especially exciting. Our collaboration will augment ImaginAb's existing CD8 development program with an anti-CD3 imaging program."

"Imaging immune function is the next frontier of diagnostic medicine and will have a major impact on how new therapeutics are developed for cancer and autoimmune diseases," commented Dr. Scott Koenig, CEO of MacroGenics. "Our collaboration with ImaginAb should benefit our internal development programs targeting CD3 and B7-H3."   

Under the terms of the agreement, ImaginAb will develop a clinical imaging strategy based on a MacroGenics' anti-CD3 antibody as a patient selection tool for ongoing clinical programs, and will engineer a high-performance CD3 binding fragment for routine clinical imaging.  In addition, ImaginAb will develop imaging strategies and reagents for MacroGenics' anti-B7-H3 therapeutic product candidate, MGA271, and related applications for its CD3-based, Re-Directed T Cell Killing DART™ (Dual-Affinity Re-Targeting) therapeutic programs in cancer.

About ImaginAb

ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging.  The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of personalized medicine by improving patient outcomes and reducing the cost of healthcare.

For more information, visit www.imaginab.com.

About MacroGenics

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector cell function.  The company has multiple research and development collaborations with major pharmaceutical companies including Boehringer Ingelheim, Les Laboratoires Servier and Pfizer, Inc. 

For more information, visit www.macrogenics.com


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
2. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
3. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
4. Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor
5. GNS Healthcare And CHDI Foundation Collaborate To Build Computer Model Of Huntingtons Disease
6. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
7. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
8. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
9. Sanofi US Launches Collaborate Activate Innovation Challenge
10. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
11. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
(Date:2/11/2016)... --  Health 2.0 , the premiere showcase and catalyst ... " 10 Year Global Retrospective ", a platform to ... ten years.   --> ... served as the preeminent thought-leader in the health tech ... companies, innovators, and patient-activists through an array of events ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Fisher House ... Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy ... at the VA Southern Nevada Healthcare System. This will be the first Fisher ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... the Pittsburgh metro area, celebrates the beginning of the latest charity campaign in ... social skills through art. Donations to this worthy cause are currently being accepted ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... , The print component of “Revolutionizing Cancer Care” is distributed within ... Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 copies and an ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been reported about ... president has access to health and wellness resources most Americans could ever dream of ... individual has a schedule as frenetic as the U.S. President. , In honor ...
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not just ... PoppersTM series, sign language translation is featured in the top right of the screen. ... PoppersTM lessons has a sign language translator to teach kids the game and how ...
Breaking Medicine News(10 mins):